Cholesterol-lowering and HDL-raising properties of lecithinated soy proteins in type II hyperlipidemic patients

• Published in: Annals of nutrition and metabolism Vol. 29; no. 6; pp. 348 - 357
• Main Authors: Sirtori, C.R, Zucchi-Dentone, C, Sirtori, M, Gatti, E, Descovich, G.C, Gaddi, A, Cattin, L, Da Col, P.G, Senin, U, Mannarino, E
• Format: Journal Article
• Language: English
• Published: Switzerland 01.01.1985
• Subjects: Adult; adults; Aged; cholesterol; Cholesterol - blood; Cholesterol, HDL - blood; diet; Female; Glycine max; high density lipoprotein; Humans; hyperlipidemia; Hyperlipoproteinemia Type II - blood; Hyperlipoproteinemia Type II - diet therapy; Lipoproteins, HDL - blood; Male; Middle Aged; patient care; phosphatidylcholines; Phosphatidylcholines - therapeutic use; Plant Proteins, Dietary - therapeutic use; soy protein; Soybean Proteins; soybeans; textured proteins; Triglycerides - blood
• ISSN: 0250-6807; 1421-9697
• DOI: 10.1159/000176991

Extract: Plasma lipoprotein changes were evaluated in 65 type II patients undergoing sequential 4-week dietary treatments with: (I) standard low-lipid diet; (II) low-lipid diet with total replacement of animal proteins with textured soy proteins containing 6% of lecithin (L-TVP); (III) standard low-lipid diet; (IV) low-lipid diet with a 50% substitution of animal proteins with L-TVP. Total cholesterolemia was significantly reduced in both periods of L-TVP administration: -18.6% during phase II (total replacement) and -13.2% during phase IV (partial replacement). High-density lipoprotein (HDL) cholesterol levels tended to increase during L-TVP administration. However, only patients in the mid- and low tertiles for HDL cholesterolemia showed a significant increase of HDL levels during L-TVP. This 'normalizing' activity of L-TVP on plasma lipoproteins, even when administered as a partial dietary substituent, may be of clinical interest for subgroups of patients at high vascular risk. (author)